Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Merck Swings To 3Q Loss On Big Charge But Raises Forecast

By LINDA A. JOHNSON , AP Medical Writer | October 27, 2017

Merck company facilities in Kenilworth, N.J. (Credit: AP Photo/Mel Evans)

Lower sales for multiple medicines and a whopping charge for a big collaboration in cancer drugs drove Merck & Co. to a third-quarter loss of $56 million.

But the Kenilworth, New Jersey, company beat Wall Street’s muted expectations and it also narrowed, and raised, its outlook for the year.

Merck on Friday reported a loss of 2 cents per share, after posting a profit of $2.18 billion, or 78 cents per share, in 2016’s third quarter.

Adjusted for non-recurring costs, earnings amounted to $1.11 per share. That’s 8 cents better than industry analysts had forecast, according to a survey by Zacks Investment Research.

Merck reported revenue of $10.33 billion in the quarter, down 2 percent from $10.54 a year earlier.

Keytruda sales nearly tripled in the quarter versus a year earlier, hitting $1.05 billion, and sales of hepatitis C-curing Zepatier jumped 185 percent to $468 million. But for Merck’s top-selling portfolio, Type 2 diabetes drugs Januvia and Janumet, sales declined 2 percent to $1.53 billion due to pricing pressure, and the Gardasil vaccine against cancer-causing human papilloma virus had a sales drop of 22 percent, to $675 million. Recent generic competition to former blockbuster cholesterol drugs Zetia and Vytorin halved their sales, to a combined $462 million.

Veterinary medicines brought in $1 billion, up 15 percent.

The latest results included a one-time charge of $2.35 billion for a new partnership with Britain’s AstraZeneca PLC to market their existing cancer drugs and develop new ones.

Merck’s key medicine portfolio revolves around Keytruda, an immuno-oncology drug approved for treating several cancer types that works by enabling the immune system to better spot and kill cancer cells. Merck will now help sell AstraZeneca’s Lynparza, a cancer drug from the new class called PARP inhibitors that’s approved for treating ovarian and fallopian tube cancer. The companies will test those drugs and an unapproved one from AstraZeneca called selumetinib against various cancer types, separately and in combination.

Merck said it now expects full-year earnings in the range of $1.78 to $1.84 including one-time items, up from its prior forecast of $1.60 to $1.72 per share. It expects revenue in the range of $40 billion to $40.5 billion, up from $39.4 billion to $40.4 billion.

(Source: Associated Press)


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE